companydata.dkcompanydata.dk

XELLIA PHARMACEUTICALS ApS: Financial statements 2024

CVR: 61094628

Source: annual report 2024, Danish Business Authority

01/01/2024 – 31/12/2024

XELLIA PHARMACEUTICALS ApS (CVR 61094628) has filed annual accounts for 2024. In 2024, the company reported revenue of DKK 1,599,382,000 and a net result of DKK 828,966,000 compared with DKK -2,384,901,000 the year before. That is a decrease of 19.5% compared with the year before. The profit margin was 51.8%. Equity in the 2024 report amounted to DKK 162,454,000. The solvency ratio was 5.1%. The company had 547 employees in the financial year.

Revenue
DKK 1,599,382,000
Gross Profit
DKK 37,013,000
Profit/Loss
DKK 828,966,000
Equity
DKK 162,454,000
Total Assets
DKK 3,200,468,000
Employees
547

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
20241.6B37M829M162.5M547
20232B-640.2M-2.4B-597.8M650
20222.2B318.4M-371.5M1.8B648
20211.8B-47M-503.1M2.1B640
20202B361.3M-115.7M2.6B624

Official annual report

View the official annual report directly on the page with a Pro subscription.

Screen every Danish company

Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.

Try company screening

Events in 2024

Michael Uhd joins the board of XELLIA PHARMACEUTICALS ApSSep 27, 2024

As of September 27, 2024, Michael Uhd has joined the board of directors of XELLIA PHARMACEUTICALS ApS.

Thomas Clement Guldager leaves the board of XELLIA PHARMACEUTICALS ApSSep 27, 2024

As of September 27, 2024, Thomas Clement Guldager has left the board of directors of XELLIA PHARMACEUTICALS ApS.

XELLIA PHARMACEUTICALS ApS: The 2023 annual report is outJun 28, 2024

XELLIA PHARMACEUTICALS ApS has published its annual report for 2023. Revenue came to DKK 1,986,816,000, and the net result was DKK -2,384,901,000.

Thomas Clement Guldager joins the board of XELLIA PHARMACEUTICALS ApSApr 11, 2024

As of April 11, 2024, Thomas Clement Guldager has joined the board of directors of XELLIA PHARMACEUTICALS ApS.

John Ramsay Stewart leaves the board of XELLIA PHARMACEUTICALS ApSApr 11, 2024

As of April 11, 2024, John Ramsay Stewart has left the board of directors of XELLIA PHARMACEUTICALS ApS.

About XELLIA PHARMACEUTICALS ApS

XELLIA PHARMACEUTICALS ApS is a Danish company of the type Anpartsselskab based in København S, founded in 1959. The company is registered under the industry Fremstilling af farmaceutiske råvarer. The company was previously named AXELLIA PHARMACEUTICALS ApS and ALPHARMA ApS. The management consists of Michael Kocher. The board consists of Søren Hostrup (chair), Alexander Sebastian Benjamin Sproedt, Hugo Mendes Marques Crespo Dos Reis and Lars Beck Madsen. The company is owned by XELLIA GROUP ApS. The company has 461 employees (2026). In 2025, the company reported revenue of DKK 1,461,516,000 and a net result of DKK 213,738,000 compared with DKK 828,966,000 the year before. Equity in the 2025 report amounted to DKK 404,569,000.

Source: annual report 2025, Danish Business Authority